Skip to content

FDA approves nivolumab in combination with AVD in cHL
Interim phase 2 analysis shows zamto-cel activity in DLBCL
Dr. Lane discusses results of triplet combo in BPCDN
New therapies push UK registries into central role
FDA approves subcutaneous mosunetuzumab in relapsed or refractory follicular lymphoma

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Thomas Martin, MD

Cellular Therapy

Thomas Martin, MD

Leukemia

Thomas Martin, MD

Lymphoma

Thomas Martin, MD

Multiple Myeloma

Thomas Martin, MD

Myelodysplastic Syndromes

Thomas Martin, MD

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

March 23, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Thomas Martin, MD

Thomas Martin, MD

by sohonews
October 16, 2024
0 Comments
Less than a minute
608 Views
1 year ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

FDA

Lymphoma, Aggressive B-Cell Lymphomas

FDA approves nivolumab in combination with AVD in cHL

March 20, 2026

Nirav shah

Cellular Therapy, Lymphoma, Aggressive B-Cell Lymphomas, Meetings / Conferences, 2025 Tandem Meetings, News

Interim phase 2 analysis shows zamto-cel activity in DLBCL

March 19, 2026

ASH 2025, Leukemia

Dr. Lane discusses results of triplet combo in BPCDN

March 18, 2026

SOHO UK, Leukemia, Acute Myeloid Leukemia, News

New therapies push UK registries into central role

March 18, 2026

Silver,Spring,,Md,,Usa,-,June,25,,2022:,The,Fda

Cellular Therapy, Lymphoma, Indolent B-Cell Lymphomas, News

FDA approves subcutaneous mosunetuzumab in relapsed or refractory follicular

March 17, 2026

SOHO Insider podcast

SOHO UK, Cellular Therapy, Lymphoma, News, SOHO Insider Podcast

Dr. Gloria Iacoboni on improving CAR T-cell therapy outcomes

March 17, 2026

Top Categories

Cellular Therapy

61

Leukemia

96

Lymphoma

104

Multiple Myeloma

82

Myelodysplastic Syndromes

32

Myeloproliferative Neoplasms

20

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Thomas Martin, MD

Cellular Therapy

Thomas Martin, MD

Leukemia

Thomas Martin, MD

Lymphoma

Thomas Martin, MD

Multiple Myeloma

Thomas Martin, MD

Myelodysplastic Syndromes

Thomas Martin, MD

Myeloproliferative Neoplasms

Subscribe

Recent Posts

FDA

FDA approves nivolumab in combination with AVD in cHL

Nirav shah

Interim phase 2 analysis shows zamto-cel activity in DLBCL

Dr. Lane discusses results of triplet combo in BPCDN

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.